Similitude in modern pharmacology

British Homeopathic Journal

Volumn 88, Issue 3, 1999, Pages 112-120

  Teixeira, M Z ^a  

^a Associacao Paulista de Homeopatia   (Brazil)

Author keywords

Rebound effect; Scientific rationality; Secondary effect; Similitude

Indexed keywords

AMPHETAMINE DERIVATIVE; ANTACID AGENT; ANTIHISTAMINIC AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRONCHODILATING AGENT; CHOLINESTERASE INHIBITOR; CLOFIBRATE; CLONIDINE; CORTICOSTEROID; DIURETIC AGENT; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOT DERIVATIVE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS LYNESTRENOL; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; GLYCERYL TRINITRATE; GUANFACINE; HEPARIN; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDANTOIN; MANNITOL; MESTRANOL PLUS NORETYNODREL; MUSCLE RELAXANT AGENT; OPIATE; ORAL CONTRACEPTIVE AGENT; OXYMETAZOLINE; PHENOTHIAZINE DERIVATIVE; PROTAMINE; SALICYLIC ACID DERIVATIVE; UNINDEXED DRUG;

AMENORRHEA; ANGINA PECTORIS; ANXIETY; ARTICLE; ASTHMA; EDEMA; EPILEPSY; GALACTORRHEA; HEART VENTRICLE ARRHYTHMIA; HOMEOPATHY; HUMAN; HYPERLIPOPROTEINEMIA; HYPERTENSION; HYPOTENSION; HYPOVOLEMIC SHOCK; INFLAMMATION; INHALATIONAL DRUG ADMINISTRATION; INTRACRANIAL HYPERTENSION; INTRANASAL DRUG ADMINISTRATION; MIGRAINE; MODEL; NOSE CONGESTION; ORAL DRUG ADMINISTRATION; PAIN; PEPTIC ULCER; PSYCHOSIS; REBOUND; SPASTICITY; THROMBOEMBOLISM; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0032802653     PISSN: 00070785     EISSN: None     Source Type: Journal    
DOI: 10.1054/homp.1999.0301     Document Type: Article

References (126)

1. The United States Pharmacopeia Dispensing Information. The United States Pharmacopeial Convention, Inc: Mack Printing Co., Easton, Pa., 1996.
2. American Hospital Formulary Service. American Society of Hospital Pharmacists. Bethesda, MD, 1990.
3. a ed. Translated by W Boericke. B. Jain Publisher: New Delhi, reimp. 1979.
4. Zulian Teixeira, M. Semelhante cura Semelhante: o princípio de cura homeopático fundamentado pela racionalidade médica e cientifica. São Paulo: Editorial Petrus, 1998.
5. Kantelip JP, Trolese JF, Cromarias PG, Duchene-Marullaz P. Effect on heart rate over 24 hours of pindolol administered for 14 days. Eur J Clin Pharmacol 1984; 27: 535-538.
6. Brodde OE, Wang XL, O'Hara N, Daul A, Schiess W. Effect of propranolol, alprenolol, pindolol, and bopindolol in beta2-adrenoceptor density in human lymphocytes. J Cardiovasc Pharmacol 1986; 8 (Suppl 6): S70-S73.
7. Lee SS, Braillon A, Girod C, Geoffroy P, Lebrec D. Haemodynamic rebound phenomena after abrupt cessation of propranolol therapy in portal hypertensive rats. J Hepatol 1986; 3: 38-41.
8. Moore LR, Corbo M, Chien YW. Development of the rabbit model for studying the effects of propranolol on cardiac contractility: relationship of intravenous pharmacodynamics and pharmacokinetics. Methods Find Exp Clin Pharmacol 1988; 10: 157-163.
9. Greenspan Am, Spielman SR, Horowitz LN, Laddu A, Senior S. The electrophysiologic properties of esmolol, a short acting beta-blocker. Int J Clin Pharmacol Ther Toxicol 1988; 26: 209-216.
10. Ebil K, Fukunaga R, Taniguchi T. et al. Effects of chronic administration of carteolol on beta-adrenoceptors in spontaneously hypertensive rat heart. Jpn J Pharmacol 1991; 56: 505-512.
11. Rehnqvist N. Tolerance development during transdermal administration of nitroglycerin in angina pectoris. Acta Pharmacol Toxicol (Copenh) 1986; 59 (Suppl 6): S113-S115.
12. Rehnqvist N, Olsson G, Engvall J. et al. Abrupt withdrawal of isosorbide-5-mononitrate in Durules (Imdur) after long term treatment in patients with stable angina pectoris. Eur Heart J 1988; 9: 1339-1347.
13. Thadani U. Role of nitrates in angina pectoris. Am J Cardiol 1992; 70: 43B-53B.
14. Thadani U, De Vane PJ. Efficacy of isosorbide mononitrate in angina pectoris. Am J Cardiol 1992; 70: 67G-71G.
15. Frishman WH. Tolerance, rebound, and time-zero effect of nitrate therapy. Am J Cardiol 1992; 70: 43G-47G; discussion 47G-48G.
16. Ferratini M. Risk of rebound phenomenon during nitrate withdrawal. Int J Cardiol 1994; 45: 89-96.
17. Held P, Olsson G. The rationale for nitrates in angina pectoris. Can J Cardiol 1995; 11 (Suppl B): 11B-13B.
18. Martsevich SY, Koutishenko N, Metelitsa VI. Abrupt cessation of short-term continuous treatment with isosorbide dinitrate may cause a rebound increase in silent myocardial ischaemia in patients with stable angina pectoris. Heart 1996; 75: 447-450.
19. Gan EK, Abdul Sattar MZ. Effect of acute and subacute treatment of clonidine on blood pH, PCO2 and PO2 in mice. Clin Exp Pharmacol Physiol 1982; 9: 675-677.
20. Taira CA, Celuch SM, Enero MA. Effects of acute and short-term treatment with antihypertensive drugs in sinoaortic denervated rats. Gen Pharmacol 1983; 14: 657-661.
21. Jain AK, Hiremath A, Michael R, Ryan JR, Mcmahon FG. Clonidine and guanfacine in hypertension. Clin Pharmacol Ther 1985; 37: 271-276.
22. Reid JL. Central alpha 2 receptors and the regulation of blood pressure in humans. J Cardiovasc Pharmacol 1985; 7 (Suppl 8): S45-S50.
23. Campbell BC, Reid JL. Regimen for the control of blood pressure and symptoms during clonidine withdrawal. Int J Clin Pharmacol Res 1985; 5: 215-222.
24. Klein C, Morton N, Kelley S, Metz S. Transdermal clonidine therapy in elderly mild hypertensives: effects on blood pressure, plasma norepinephrine and fasting plasma glucose. J Hypertens Suppl 1985; 3: S81-S84.
25. Leckman JF, Ort S, Caruso KA, Anderson GM, Riddle MA, Cohen DJ. Rebound phenomena in Tourette's syndrome after abrupt withdrawal of clonidine. Behavioral, cardiovascular, and neurochemical effects. Arch Gen Psychiatry 1986; 43: 1168-1176.
26. Jarrott B, Lewis SJ, Doyle AE, Louis WJ. Effects of continuous infusions (10 days) and cessation of infusions of clonidine and rilmenidine (S3341) on cardiovascular and behavioral parameters of spontaneously hypertensive rats. Am J Cardiol 1988; 61: 39D-44D.
27. Muizelaar JP, Wei EP, Kontos HA, Becker DP. Mannitol causes compensatory cerebral vasoconstriction and vasodilation in response to blood viscosity changes. J Neurosurg 1983; 59: 822-828.
28. Domaingue CM, Nye DH. Hypotensive effect of mannitol administered rapidly. Anaesth Intensive Care 1985; 13: 134-136.
29. Kotwica Z, Persson L. Effect of mannitol on intracranial pressure in focal cerebral ischemia - An experimental study in a rat. Mater Med Pol 1991; 23: 280-284.
30. Davis M, Lucatorto M. Mannitol revisited. J Neurosci Nurs 1994; 26: 170-174.
31. Cayen MN, Kallai-Sanfacon MA, Dubuc J, Greselin E, Dvornik D. Effect of AY-25,712 on fatty acid metabolism in rats. Atherosclerosis 1982 45: 281-290.
32. Arsenio L, Caronna S, Lateana M, Magnati G, Strata A, Zammarchi G. [Hyperlipidemia, diabetes and atherosclerosis: efficacy of treatment with pantethine]. Acta Biomed Ateneo Parmense 1984; 55: 25-42.
33. Chouinard G, Labonte A, Fontaine R, Annable L. New concepts in benzodiazepine therapy: rebound anxiety and new indications for the more potent benzodiazepines. Prog Neuropsychopharmacol Biol Psychiatry 1983; 7: 669-673.
34. Swinson RP, Pecknold JC, Kirby ME. Benzodiazepine dependence. J Affect Disord 1987; 13: 109-118.
35. Lader M. Long-term treatment of anxiety: benefits and drawbacks. Psychopharmacol Ser 1988; 5: 169-179.
36. Pecknold JC, Swinson RP, Kuch K, Lewis CP. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. III. Discontinuation effects. Arch Gen Psychiatry 1988; 45: 429-436.
37. Tesar GE. High-potency benzodiazepines for short-term management of panic disorder: the U.S. experience. J Clin Psychiatry 1990; 51 (Suppl 4-10): discussion S50-S53.
38. Kales A. Benzodiazepine hypnotics and insomnia. Hosp Pract (Off Ed) 1990; 25 (Suppl 3: 7-21): discussion S22-S23.
39. Teboul E, Chouinard G. A guide to benzodiazepine selection. Part II: Clinical aspects. Can J Psychiatry 1991; 36: 62-73.
40. Noyes R Jr, Garvey MJ, Cook B, Suelzer M. Controlled discontinuation of benzodiazepine treatment for patients with panic disorder. Am J Psychiatry 1991; 148: 517-523.
41. Ansseau M, Von Frenckell R. [Value of prazepam drops in the brief treatment of anxiety disorders]. Encephale 1991; 17: 291-294.
42. Schweizer E, Patterson W, Rickels K, Rosenthal M. Double-blind, placebo-controlled study of a once-a-day, sustained-release preparation of alprazolam for the treatment of panic disorder. Am J Psychiatry 1993; 150: 1210-1215.
43. Vgontzas AN, Kales A, Bixler EO. Benzodiazepine side effects: role of pharmacokinetics and pharmacodynamics. Pharmacology 1995; 51: 205-223.
44. Mandos LA, Rickels K, Cutler N, Roeschen J, Keppel Hesselink JM, Schweizer E. Placebo-controlled comparison of the clinical effects of rapid discontinuation of ipsapirone and lorazepam after 8 weeks of treatment for generalized anxiety disorder. Int Clin Psychopharmacol 1995; 10: 251-256.
45. Porrino LJ, Rapoport JL, Behar D, Ismond DR, Bunney WE Jr. A naturalistic assessment of the motor activity of hyperactive boys. Stimulant drug effects. Arch Gen Psychiatry 1983; 40: 688-693.
46. Hernandez L, Parada M, Hoebel BG. Amphetamine-induced hyperphagia and obesity caused by intraventricular or lateral hypothalamic injections in rats. J Pharmacol Exp Ther 1983; 227: 524-530.
47. Wolgin DL, Salisbury JJ. Amphetamine tolerance and body weight set point: a dose-response analysis. Behav Neurosci 1985; 99: 175-185.
48. Winslow JT, Insel TR. Serotonergic modulation of rat pup ultrasonic vocal development: studies with 3,4-methylenedioxymethamphetamine. J Pharmacol Exp Ther 1990; 254: 212-220.
49. Touret M, Sallanon-Moulin M, Jouvet M. Awakening properties of modafinil without paradoxical sleep rebound: comparative study with amphetamine in the rat. Neurosci Lett 1995; 189: 43-46.
50. Obal F Jr, Benedek G, Lelkes Z, Obal F. Effects of acute and chronic treatment with amitryptyline on the sleep-wake activity of rats. Neuropharmacology 1985; 24: 223-229.
51. Corral M, Sivertz K, Jones BD. Transient mood elevation associated with antidepressant drug decrease. Can J Psychiatry 1987; 32: 764-767.
52. Steiger A. Effects of clomipramine on sleep EEG and nocturnal penile tumescence: a long-term study in a healthy man. J Clin Psychopharmacol 1988; 8: 349-354.
53. Gillin JC, Sutton L, Ruiz C. et al. The effects of scopolamine on sleep and mood in depressed patients with a history of alcoholism and a normal comparison group. Biol Psychiatry 1991; 30: 157-169.
54. Maudhuit C, Jolas T, Lainey E, Hamon M, Adrien J. Effects of acute and chronic treatment with amoxapine and cericlamine on the sleep-wakefulness cycle in the rat. Neuropharmacology 1994; 33: 1017-1025.
55. Kupfer DJ, Pollock BG, Perel JM, Miewald JM, Grochocinski VJ, Ehlers CL. Effect of pulse loading with clomipramine on EEG sleep. Psychiatry Res 1994; 54: 161-175.
56. Marciani MG, Gotman J, Andermann F, Olivier A. Patterns of seizure activation after withdrawal of antiepileptic medication. Neurology 1985; 35: 1537-1543.
57. Ries CR, Scoates PJ, Puil E. Opisthotonos following propofol: a nonepileptic perspective and treatment strategy. Can J Anaesth 1994; 41: 414-419.
58. Ramkumar V, El-Fakahany EE. Changes in the affinity of [3H]nimodipine binding sites in the brain upon chlorpromazine treatment and subsequent withdrawal. Res Commun Chem Pathol Pharmacol 1985; 48: 463-466.
59. Van Sweden B. Rebound insomnia in neuroleptic drug withdrawal neurophysiologic characteristics. Pharmacopsychiatry 1987; 20: 116-119.
60. Costall B, Naylor Rj, Tyers MB. The psychopharmacology of 5-HT3 receptors. Pharmacol Ther 1990; 47: 181-202.
61. Minabe Y, Tsutsumi M, Kurachi M. Effects of chronic haloperidol treatment on amygdaloid seizure generation in cats. Psychopharmacology (Berlin) 1988; 94: 259-262.
62. Caul WF, Jones JR, Schmidt TA, Murphy SM, Barrett RJ. Rebound cue state following a single dose of haloperidol. Life Sci 1991; 49: PL119-PL124.
63. Haggstrom JE. Effects of sulphide on persistent neuroleptic-induced dyskinesia in monkeys. Acta Psychiatr Scand Suppl 1984; 311: 103-108.
64. Lublin H, Gerlach J, Hagert U. et al. Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist in tardive dyskinesia. Eur Neuropsychopharmacol 1991; 1: 541-548.
65. Tamminga CA, Thaker GK, Moran M, Kakigi T, Gao XM. Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry 1994; 55 (Suppl B): S102-S106.
66. Mckirdy HC, Marshall RW. Effect of drugs and electrical field stimulation on circular muscle strips from human lower oesophagus. Q J Exp Physiol 1985; 70: 591-601.
67. Gaba SJ, Bourgouin-Karaouni D, Dujois P, Michel FB, Prefaut C. Effects of adenosine triphosphate on pulmonary circulation in chronic obstructive pulmonary disease. ATP: a pulmonary vasoregulator? Am Rev Respir Dis 1986; 134: 1140-1144.
68. Lefebvre RA, Burnstock G. Effect of adenosine triphosphate and related purines in the rat gastric fundus. Arch Int Pharmacodyn Ther 1990; 303: 199-215.
69. Postorino A, Serio R, Mule F. On the purinergic system in rat duodenum: existence of P1 and P2 receptors on the smooth muscle. Arch Int Physiol Biochim 1990; 98: 53-58.
70. Maggi CA, Giuliani S. Multiple inhibitory mechanisms mediate non-adrenergic non-cholinergic relaxation in the circular muscle of the guinea-pig colon. Naunyn Schmiedebergs Arch Pharmacol 1993; 347: 630-634.
71. Bartho L, Lefebvre RA. Nitric oxide-mediated contraction in enteric smooth muscle. Arch Int Pharmacodyn Ther 1995; 329: 53-66.
72. Copeland RL Jr, Pradhan SN. Effect of morphine on self-stimulation in rats and its modification by chloramphenicol. Pharmacol Biochem Behav 1988; 31: 933-935.
73. Millan MJ, Colpaert FC. Opioid systems in the response to inflammatory pain: sustained blockade suggests role of kappa- but not mu-opioid receptors in the modulation of nociception, behaviour and pathology. Neuroscience 1991; 42: 541-553.
74. Ekblom M, Hammarlund-Udenaes M, Paalzow L. Modeling of tolerance development and rebound effect during different intravenous administration of morphine to rats. J Pharmacol Exp Ther 1993; 266: 244-252.
75. Espejo EF, Stinus L, Cador M, Mir D. Effects of morphine and naloxone on behaviour in the hot plate test: an ethopharmacological study in the rat. Psychopharmacology (Berl) 1994; 113: 500-510.
76. National Headache Foundation, 428 W. St. James Pl., 2° andar, Chicago, Illinois 60614-2750.
77. Silberstein SD, Schulman EA, Hopkins MM. Repetitive intravenous DHE in the treatment of refractory headache. Headache 1990; 30: 334-339.
78. Yamaki K, Nakagawa H, Tsurufuji S. Inhibitory effects on anti-inflammatory drugs on type II collagen induced arthritis in rats. Ann Rheum Dis 1987; 46: 543-548.
79. Maddux JM, Keeto KS. Effects of dexamethasone, levamisole, and dexamethasone-levamisole combination on neutrophil function in female goats. Am J Vet Res 1987; 48: 1114-1119.
80. Seppala E, Laitinen O, Vapaatalo H. Comparative study on the effects of acetyl acid, indomethacin and paracetamol on metabolites of arachidonic acid in plasma, serum and urine in man. Int J Clin Pharmacol Res 1983; 3: 265-269.
81. Endres S, Whitaker RE, Ghorbani R, Meydani SN, Dinarello CA. Oral aspirin and ibuprofen increase cytokine-induced synthesis of IL-1 beta and of tumour necrosis factor-alpha ex vivo. Immunology 1996; 87: 264-270.
82. Averkov OV, Zateishchikov DA, Gratsianskii NA Logutov IA, Iavelov IS, Ianus VM. [Unstable angina: effect of aspirin and heparin on treatment outcome in hospital patients (a double-blind, placebo-controlled study)]. Kardiologiia 1993; 33: 4-9.
83. Kuitunen AH, Salmenpera MT, Heinonen J, Rasi VP, Myllyla G. Heparin rebound: a comparative study of protamine chloride and protamine sulfate in patients undergoing coronary artery bypass surgery. J Cardiothorac Vasc Anesth 1991; 5: 221-226.
84. Subramaniam P, Skillington P, Tatoulis J. Heparin-rebound in the early postoperative phase following cardiopulmonary bypass. Aust NZ J Surg 1995; 65: 331-333.
85. Pastel RH, Echevarria E, Cox B, Blackburn TP, Tortella FC. Effects of chronic treatment with two selective 5-HT2 antagonists on sleep in the rat. Pharmacol Biochem Behav 1993; 44: 797-804.
86. Loew D, Barkow D, Schuster O, Knoell HE. Pharmacokinetic and pharmacodynamic study of the combination of furosemide retard and triamterene. Eur J Clin Pharmacol 1984; 26: 191-195.
87. Sjostrom PA, Beermann BA, Odlind BG. Delayed tolerance to furosemide diuresis. Influence of angiotensin converting enzyme inhibition by lisinopril. Scand J Urol Nephrol 1988; 22: 317-325.
88. Scheen AJ. Dose-response curve for torasemide in healthy volunteers. Arzneimittelforschung 1988; 38: 156-159.
89. Reyes AJ. Effects of diuretics on outputs and flows of urine and urinary solutes in healthy subjects. Drugs 1991; 41 (Suppl 3): S35-S59.
90. Knauf H, Spahn H, Mutschler E. The loop diuretic torasemide in chronic renal failure. Pharmacokinetics and pharmacodynamics. Drugs 1991; 41 (Suppl 3): S23-S34.
91. Reyes AJ, Leary WP. Renal excretory responses to single and repeated administration of diuretics in healthy subjects: clinical connotations. Cardiovasc Drugs Ther 1993; 7 (Suppl 1): S29-S44.
92. De Jonge JW, Knottnerus JA, Van Zutphen WM, De Bruijne GA, Struijker Boudier HA. Short term effect of withdrawal of diuretic drugs prescribed for ankle oedema. BMJ 1994; 308: 511-513.
93. Vree TB, Van Den Biggelaar-Martea M, Verwey-Van Wissen CP. Furosemide and its acyl glucuronide show a short and long phase in elimination kinetics and pharmacodynamic effect in man. J Pharm Pharmacol 1995; 47: 964-969.
94. Kozol R, Fromm D, Ray TK. Effects of a naturally occurring polyamine on acid secretion by isolated gastric mucosa. Proc Soc Exp Biol Med 1984; 175: 52-57.
95. Ruckebusch Y, Malbert CH, Crichlow EC. Hexamethonium: a probe to assess autonomic nervous system involvement in upper gastrointestinal functions in conscious sheep. Vet Res Commun 1987; 11: 293-303.
96. Ekblad EB, Licko V. Conservative and nonconserative inhibitors of gastric acid secretion. Am J Physiol 1987; 253: G359-G368.
97. Rigaud D, Dubrasquet M, Accary JP, Laigneau JP, Lewin MJ. Sequential somatostatin and gastrin releases in response to secretin in rat in vivo. Gastroenterol Clin Biol 1991; 15: 717-722.
98. Fullarton GM, Macdonald AM, Mccoll KE. Rebound hypersecretion after H2-antagonist withdrawal - a comparative study with nizatidine, ranitidine and famotidine. Aliment Pharmacol Ther 1991; 5: 391-398.
99. Debongnie JC. Current aspects of H2 receptor antagonists in the treatment of ulcers. Acta Gastroenterol Belg 1992; 55: 415-422.
100. Kubo K, Uehara A, Kubota T, Nozu T. et al. Effects of ranitidine on gastric vesicles containing H + ,K+-adenosine triphosphatase in rats. Scand J Gastroenterol 1995; 30: 944-951.
101. Herzog P. Effect of antacids on mineral metabolism. Z Gastroenterol 1983; 21 (Suppl): S117-S126.
102. Hade JE, Spiro HM. Calcium and acid rebound: a reappraisal. J Clin Gastroenterol 1992; 15: 37-44.
103. Mones J, Carrio I, Sainz S. et al. Gastric emptying of two radiolabelled antacids with simultaneous monitoring of gastric pH. Eur J Nucl Med 1995; 22: 1123-1128.
104. Hurlimann S, Michel K, Inauen W, Halter F. Effect of Rennie Liquid versus Maalox Liquid on intragastric pH in a double-blind, randomized, placebo-controlled, triple cross-over study in healthy volunteers. Am J Gastroenterol 1996; 91: 1173-1180.
105. Svedmyr N. Action of corticosteroids on beta-adrenergic receptors. Clinical aspects. Am Rev Respir Dis 1990; 141 (Suppl): S31-S38.
106. Svedmyr N. The current place of beta 2-agonists in the management of asthma. Lung 1990; 168 (Suppl): S105-S110.
107. Cochrane GM. Bronchial asthma and the role of beta 2-agonists. Lung 1990; 168 (Suppl): S66-S70.
108. Beach JR, Yong CL, Harkawat R. et al. Effect on airway responsiveness of six weeks treatment with salmeterol. Pulm Pharmacol 1993; 6: 155-157.
109. Yates DH, Sussman HS, Shaw MJ, Barnes PJ, Chung KF. Regular formoterol treatment in mild asthma. Effect on bronchial responsiveness during and after treatment. Am J Respir Crit Care Med 1995; 152: 1170-1174.
110. De Jong JW, Van Der Mark TW, Koeter GH, Postma DS. Rebound airway obstruction and responsiveness after cessation of terbutaline: effects of budesonide. Am J Respir Crit Care Med 1996; 153: 70-75.
111. Verbeek PR, Geerts WH. Nontapering versus tapering prednisone in acute exacerbations of asthma: a pilot trial. J Emerg Med 1995; 13: 715-719.
112. Graf P, Juto JE. Decongestion effect and rebound swelling of the nasal mucosa during 4-week use of oxymetazoline. ORL J Otorhinolaryngol Relat Spec 1994; 56: 157-160.
113. Graf P, Hallen H, Juto JE. Four-week use of oxymetazoline nasal spray (Nezeril) once daily at night induces rebound swelling and nasal hyperreactivity. Acta Otolaryngol (Stockh) 1995; 115: 71-75.
114. Graf P, Hallen H, Juto JE. Benzalkonium chloride in a decongestant nasal spray aggravates rhinitis medicamentosa in healthy volunteers. Clin Exp Allergy 1995; 25: 395-400.
115. Graf P, Hallen H, Juto JE. The pathophysiology and treatment of rhinitis medicamentosa. Clin Otolaryngol 1995; 20: 224-229.
116. Belmonte C, Bartels SP, Liu JH, Neufeld AH. Effects of stimulation of the ocular sympathetic nerves on IOP and aqueous humor flow. Invest Ophthalmol Vis Sci 1987; 28: 1649-1654.
117. Shapiro AG, Thomas L. Efficacy of bromocriptine versus breast binders as inhibitors of postpartum lactation. South Med J 1984; 77: 719-721.
118. European Multicentre study group for cabergoline in lactation inhibition. Single dose cabergoline versus bromocriptine in inhibition of puerperal lactation: randomised, double blind, multicentre study. BMJ 1991; 302: 1367-1371.
119. Webster J. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperproactinaemia and inhibition of lactation. Drug Saf 1996; 14: 228-238.
120. Kovacs I. Experimentation of the rebound effect of biphasic oral contraceptives. Ther Hung 1990; 38: 110-113.
121. Roland M. Observations on patients with anovulatory cycles and amenorrhoea when Enovid is administered. Proc Symp On Progestational Steroids. Chicago, 1957.
122. Tyler ET, Olson HJ. Clinical use of new progestational steroids in infertility. Ann N Y Acad Sci 1958; 71: 704.
123. Garcia CR, Pincus G. Effects of three 19-nor steroids on human ovulation and menstruation. Amer J Obstet Oynec 1958; 75: 82.
124. Borglin N. Inhibitory effect of Lynestrenol and Lyndiol on human ovarian function. Int J Fertil 1964; 9: 17.
125. Kirchhoff JH, Haller J. Klinische Erfahrungen mit einem Östrogen-Gestagen kombination. Med Klin 1964; 59: 681.
126. Szontágh F. Experiences with Infecundin tablets. Therapia Hung 1968; 16: 1.